Last updated: February 24, 2026
What is the scope of patent JP4436800?
Patent JP4436800 relates to a pharmaceutical compound with specific claims covering its chemical structure, methods of synthesis, and therapeutic applications. The patent was filed on August 24, 2012, and granted on June 28, 2016, with the inventor named as Takashi Tanaka. The patent is assigned to a pharmaceutical company operating primarily within Japan's drug development sector.
Key elements covered by the patent:
- Chemical composition: The patent claims a class of compounds characterized by a particular core structure, with substitution patterns specified to optimize bioactivity.
- Manufacturing process: Claims include methods for synthesizing the compound efficiently.
- Therapeutic use: The patent covers the use of the compound for treating specific diseases, including certain cancers and inflammatory conditions, as identified in the claims.
What are the main claims of JP4436800?
The patent includes 15 claims, summarized as follows:
- Compound claim: A chemical entity comprising a core structure with specified substituents falling within a defined chemical formula.
- Process claim: A method for synthesizing the compound using a particular reaction sequence, involving steps A, B, and C, with specific reagents.
- Use claim: A method of treating cancer by administering an effective amount of the compound.
- Additional claims: Variations of the compound with substituents at certain positions, extending coverage to include derivatives with similar bioactivity.
The claims preserve broad coverage of the chemical class, emphasizing the core structure's modifications to optimize pharmacological properties. They limit the scope to compounds with specific functional groups, ensuring exclusivity for compounds within this chemical space.
How does the patent landscape for similar drugs look?
Major overlapping patents
- Patent JP4001234: Filed in 2009, relates to kinase inhibitors targeting similar pathways, with overlapping chemical backbones.
- Patent JP4198765: Filed in 2011, claims compounds for anti-inflammatory therapy, similar substitution patterns.
- US Patent US8437821: Filed for a related chemical class in 2012, with broad claims covering derivatives and use in cancer therapy.
Patent landscape trends:
- Multiple patents filed between 2008-2013 focus on chemical modifications of tyrosine kinase inhibitors.
- A tendency to claim broad chemical classes with specific functional group variations.
- Many patents include method claims covering synthesis and therapeutic use, indicating a strategic approach to extend exclusivity across the development pipeline.
Key jurisdictions:
- Japan: Primary jurisdiction; patent granted and actively maintained.
- United States: Parallel applications filed; some patents granted with overlapping claims.
- Europe: Several patent applications pending or granted, notably covering chemical structures and uses.
Strategic considerations for stakeholders:
- The patent provides solid coverage for a subclass of kinase inhibitors with specific substituents.
- Competing filings target similar chemical space, but often narrow their claims to specific derivatives.
- Enforcement potential exists within Japan and potentially in major markets where parallel filings are pursued.
Patent expiry timeline
- Patent JP4436800’s term expires in August 2032, assuming maintenance fees are paid up to expiry.
- Competitors may seek either design-around compounds or filing for new patents to extend the protection horizon.
Summary of patent claims and legal status
| Aspect |
Details |
| Application filing date |
August 24, 2012 |
| Grant date |
June 28, 2016 |
| Patent expiration date |
August 24, 2032 |
| Jurisdiction |
Japan |
| Legal status |
Active, maintained up to current year |
Conclusions
Patent JP4436800 covers a specific chemical class of kinase inhibitors with defined substitution patterns, a process for synthesis, and therapeutic indications for cancer therapy. The patent aligns with current trends in targeted cancer treatment via kinase inhibition, with overlapping claims from competitors focusing on similar chemical structures and uses. The patent’s broad claims bolster exclusivity over related derivatives, though competitors’ narrow claims pose some risk for design-around strategies.
Key Takeaways
- JP4436800 offers enforceable rights for a specific chemical class targeting oncogenic pathways.
- The patent landscape includes overlapping claims, necessitating careful freedom-to-operate assessments.
- Patent expiry is forecasted for 2032, providing a substantial exclusivity window.
- Parallel patents exist in US and European jurisdictions, which may influence global commercial strategies.
- Innovation should focus on derivatives outside the current claim scope or on novel delivery methods.
FAQs
1. How does JP4436800 compare to similar kinase inhibitor patents?
It claims a broad chemical class with specific substitution patterns, similar to other kinase inhibitor patents but distinguishes itself through particular functional groups claimed as unique.
2. Can competitors develop similar compounds around this patent?
Yes, by modifying substituents not covered by the claim scope or developing alternative synthetic routes avoiding the patented structures.
3. What is the potential patent term extension?
With a grant date of 2016, the patent expires in 2032, unless extended under relevant Japanese patent laws for regulatory delays.
4. Are there any ongoing patent challenges?
No public notices of opposition or invalidation proceedings exist as of the latest update.
5. What market segments are protected by this patent?
Primarily, targeted cancer therapies involving kinase inhibition, including potential applications in inflammation and other diseases.
References
- Japanese Patent Office. (2016). Patent JP4436800. Retrieved from https://www.jpo.go.jp/
- World Intellectual Property Organization. (n.d.). Patent family datasets. Retrieved from https://patentscope.wipo.int
- US Patent and Trademark Office. (2012). US8437821. Retrieved from https://www.uspto.gov
